- Home
- EVAX vs MEGL Comparison
EVAX vs MEGL Comparison
Compare EVAX & MEGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- MEGL
- Stock Information
- Founded
- EVAX 2008
- MEGL 2016
- Country
- EVAX Denmark
- MEGL Hong Kong
- Employees
- EVAX N/A
- MEGL N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- MEGL Finance: Consumer Services
- Sector
- EVAX Health Care
- MEGL Finance
- Exchange
- EVAX Nasdaq
- MEGL Nasdaq
- Market Cap
- EVAX 16.3M
- MEGL 9.0M
- IPO Year
- EVAX 2021
- MEGL 2022
- Fundamental
- Price
- EVAX $1.79
- MEGL $1.37
- Analyst Decision
- EVAX Strong Buy
- MEGL
- Analyst Count
- EVAX 3
- MEGL 0
- Target Price
- EVAX $33.33
- MEGL N/A
- AVG Volume (30 Days)
- EVAX 211.9K
- MEGL 265.0K
- Earning Date
- EVAX 03-26-2025
- MEGL 04-21-2025
- Dividend Yield
- EVAX N/A
- MEGL N/A
- EPS Growth
- EVAX N/A
- MEGL N/A
- EPS
- EVAX N/A
- MEGL N/A
- Revenue
- EVAX $3,295,000.00
- MEGL $1,976,138.00
- Revenue This Year
- EVAX $9,039.73
- MEGL N/A
- Revenue Next Year
- EVAX $1.47
- MEGL N/A
- P/E Ratio
- EVAX N/A
- MEGL N/A
- Revenue Growth
- EVAX N/A
- MEGL 67.75
- 52 Week Low
- EVAX $1.70
- MEGL $0.41
- 52 Week High
- EVAX $22.05
- MEGL $3.06
- Technical
- Relative Strength Index (RSI)
- EVAX 35.07
- MEGL 55.56
- Support Level
- EVAX $1.75
- MEGL $1.29
- Resistance Level
- EVAX $1.99
- MEGL $1.45
- Average True Range (ATR)
- EVAX 0.17
- MEGL 0.26
- MACD
- EVAX 0.05
- MEGL -0.05
- Stochastic Oscillator
- EVAX 10.70
- MEGL 7.85
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.